Skip to main content
. 2017 Mar 28;4(1):57–69. doi: 10.1007/s40744-017-0060-8

Fig. 3.

Fig. 3

Clinical and patient-reported outcomes for CZP ITT patients (N = 235), and the CZP monotherapy (n = 110) and CZP + MTX (n = 125) sub-populations: a HAQ-DI (absolute values, LOCF); b pain (PAAP; absolute values, LOCF); c fatigue (absolute values, LOCF); d PtGADA (absolute values, LOCF)